Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of lurbinectedin alone or lurbinectedin + irinotecan versus topotecan in relapsed small cell lung cancer
CTR20242892Phase 3Active
- Sponsor
- PharmaMar
- Start
- Sep 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lurbinectedin, irinotecan, topotecan in small cell lung cancer (SCLC), sponsored by PharmaMar. Started Sep 2024; status: active.
02
Drugs
lurbinectedinirinotecantopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20242892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242892.